Akebia Therapeutics Inc
F:AX9
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Akebia Therapeutics Inc
F:AX9
|
US |
|
A
|
Arbor Realty Trust Inc
F:OWQ
|
US |
|
F
|
FirstEnergy Corp
SWB:FE7
|
US |
|
ON Semiconductor Corp
NASDAQ:ON
|
US |
|
S
|
Societe BIC SA
XMUN:BIF
|
FR |
|
F
|
First Tin PLC
F:1SN
|
UK |
|
Ypsomed Holding AG
F:OWX
|
CH |
Wall St Price Targets
AX9 Price Targets Summary
Akebia Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for AX9 is 3.567 EUR with a low forecast of 0.883 EUR and a high forecast of 5.508 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is AX9's stock price target?
Price Target
3.567
EUR
According to Wall Street analysts, the average 1-year price target for AX9 is 3.567 EUR with a low forecast of 0.883 EUR and a high forecast of 5.508 EUR.
What is the Revenue forecast for Akebia Therapeutics Inc?
Projected CAGR
9%
The compound annual growth rate for Revenue over the next 8 years is 9%.
What is the Gross Profit forecast for Akebia Therapeutics Inc?
Projected CAGR
-6%
The compound annual growth rate for Gross Profit over the next 3 years is -6%.
What is the Operating Income forecast for Akebia Therapeutics Inc?
Projected CAGR
34%
The compound annual growth rate for Operating Income over the next 8 years is 34%.